ArticleJournal of orthopaedic translation2025
Oncostatin-M functionalized cryogel microspheres for promoting diabetic bone defects regeneration.
Article in Journal of orthopaedic translation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Lymphatic incorporated biomimetic scaffold enhances Osteoangio-lymphogenic coupling via HIF-1α mediated mitochondrial reprogramming for osteoporotic bone repair.Bioactive materials · 2026Article
- Piezo1 mediated scaffold-free rapid generation of self-mineralized bone organoids via activating Wnt signaling.Materials today. Bio · 2026Article
- Functionalized GelMA-based hydrogels for osteoimmunomodulation and bone regeneration.Frontiers in bioengineering and biotechnology · 2026Review
- An Emodin-Depot Microsphere-in-Hydrogel Reprograms the Immuno-myogenic Niche to Enable Volumetric Muscle Loss Repair Revealed by Single-Cell Profiling.Research (Washington, D.C.) · 2026Article
- Decellularized extracellular matrix bio-patch with strong and biodegradable wet adhesive interface for sutureless soft tissue defect repair.Journal of nanobiotechnology · 2025Article
- Editorial: From molecular insights to innovative implants in degenerative skeletal disorders.Journal of orthopaedic translation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objective: Bone defects, especially those associated with diabetes, pose a significant challenge due to impaired healing capabilities. Methods: We systematically investigated the Results: 50 ng/ml OSM can enhance migration and osteogenic differentiation of BMSCs, and angiogenesis Conclusion: The multifunctional properties of OSM/MS, including stem cell recruitment, osteogenesis, immunomodulation, and angiogenic induction, make it an effective approach for promoting bone regeneration in challenging diabetic conditions. This research not only lay the groundwork for the clinical utilization of OSM, but also presents a novel bioactive microsphere-based strategy for the management of diabetic bone defects. The translational potential of this article: The ability of OSM/MS to promote endogenous stem cell recruitment, modulate the immune-osteogenesis microenvironment, and induce angiogenesis makes it a potent candidate for diabetic bone defects. The injectable and porous nature of OSM/MS facilitates minimally invasive delivery and integration with the irregular bone defect site. In particular, OSM/MS face fewer regulatory hurdles compared with traditional tissue engineering strategy due to the lack of cellular components. Given the significant unmet clinical need and the promising
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.